

Pre-operative scoring system to determine the surgical strategy for periprosthetic hip infection

Kenichi Oe · Hirokazu Iida · Narumi Ueda ·
Tomohisa Nakamura · Naofumi Okamoto · Yusuke Ueda

Received: 5 May 2014 / Accepted: 30 July 2014 / Published online: 17 August 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract

Purpose The aim of this study was to evaluate the results of one- and two-stage revision total hip arthroplasties (THAs) and to determine a rational surgical treatment strategy for periprosthetic hip infections.

Methods We constructed a 12-point preoperative scoring system to suggest either one- or two-stage revision THAs, based on a retrospective analysis of 55 operative procedures. Prosthesis survival was analysed using the Kaplan-Meier method, and the validity of the scoring system was evaluated using receiver-operating characteristic curves.

Results At the end point of implant removal due to recurrent infection, the ten year survival rates were 94 and 87 % for one- and two-stage revision THAs, respectively. One-stage revision THA was recommended for patients scoring >9 points. The risk of recurrent infection in patients scoring 4 points was 83 %. The sensitivity and specificity of a cut-off value of 4 points, determined by the scoring system, were 83 and 100 %, respectively.

Conclusions The novel pre-operative scoring system was useful for the management of periprosthetic hip infections.

Keywords Infection · Total hip arthroplasty · One-stage revision · Two-stage revision · Scoring system

Introduction

Treatments for periprosthetic hip infections remain controversial and are particularly challenging because most patients require implant removal. In North America, the gold standard

treatment for periprosthetic hip infection is two-stage revision total hip arthroplasty (THA). In contrast, in Europe, one-stage revision THA, which includes replacement of the prosthesis during the same surgical procedure, is often preferred. This is likely because one-stage revision THA usually employs an antibiotic-loaded acrylic cement (ALAC) [1], and for over a decade, the North American trend has been towards the use of ‘cementless’ techniques. According to some meta-analyses, the infection control rate in two-stage revision THAs, using ALAC, was 88–93 %, whereas that for one-stage revision THAs, also with ALAC, was 82–86 % [2–5]. On the other hand, without ALAC, infection control was achieved in 82–91 % of two-stage revision THA cases and in 56–59 % of one-stage revision THAs [2–5]. The two-stage revision THA is safe, but has the disadvantages of requiring a second operation and having higher associated costs. Currently, there are algorithms and staging systems for periprosthetic hip infections [6–10], so it may be common for surgeons to employ one- or two-stage revision THA as the situation demands. However, a scoring system is not available to definitively determine the appropriate surgical strategy for patients with periprosthetic hip infections.

We performed one- and two-stage revision THAs for periprosthetic hip infection, according to various published criteria [6, 7, 9–12]. Here, we attempted to set up a scoring system for the pre-operative evaluation of one- and two-stage revision THAs, based on a retrospective analysis of 55 cases. The aim of this study was to report the scoring system and to determine a rational surgical treatment strategy. The hypothesis of the study was that a scoring system would facilitate better management of periprosthetic hip infections.

Patients and methods

Between February 2001 and December 2011, 68 consecutive revision THAs were performed at our institution for

K. Oe (✉) · H. Iida · N. Ueda · T. Nakamura · N. Okamoto ·
Y. Ueda

Department of Orthopaedic Surgery, Kansai Medical University,
2-5-1 Shinmachi, Hirakata-city, Osaka 573-1010, Japan
e-mail: oeken@hirakata.kmu.ac.jp

periprosthetic hip infections. One-stage revision THAs were performed on 21 hips; two-stage revision THAs were performed on 47 hips. The two-stage revision THAs included six multiple-stage revision THAs that required \geq two debridements and a single implantation. Periprosthetic hip infection or healing was evaluated according to the criteria of Giulieri et al. [13]. Infection was diagnosed if a sinus tract was present and communicating with the joint space or if at least two of the following criteria were met: (1) a positive bacterial culture from at least one intra-operative tissue specimen or the joint aspirate, (2) the presence of neutrophils in the tissue specimens, (3) clinical and laboratory signs of infection or (4) radiological signs of infection. Healing was defined as the lack of clinical signs and symptoms of infection, a C-reactive protein (CRP) level <10 mg/l or an erythrocyte sedimentation rate <20 mm/h and the absence of radiological signs of infection at the follow-up visit >24 months after the first revision. Therefore, a successful case was defined as the absence of infection at the >24 -month, post-revision follow-up visit; failure was defined as implant removal due to recurrent infection. Of the total number of patients undergoing revision THAs, 13 returned to their original referring hospital and were lost to follow-up. Based on telephone consultations, the 13 patients did not undergo additional revisions, but were excluded from the analysis. In this study, therefore, a total of 55 hips were analysed (Fig. 1) in 43 women and 12 men. The patients had a mean age, at the time of surgery, of 66 (range 34–90) years. Infected implants were associated with THAs in 32 patients and hemiarthroplasties in 23 patients.

In accordance with published criteria [6, 7, 9–12], one-stage revision THA was performed if (1) the patient's general condition was good, (2) wound complications were absent, (3) the pathogen(s) was antibiotic sensitive and (4) the bone defect requiring reconstruction was small. Two-stage revision THA was performed in cases that did not meet the criteria for one-stage revision THA, but the final decision was made intraoperatively by the surgeon [14]. All patients received cemented THAs with custom-mixed ALAC, according to the reported bacterial sensitivities determined from the pre-operative aspirates. Over 3.6 g of antibiotic per 40 g of cement was used in the first stage of two-stage revision THAs, and 1.0–2.0 g of antibiotic per 40 g of cement was used in the second stage of two-stage revision THAs and in one-stage revision THAs (Endurance Bone Cement, DePuy International, Leeds, UK).


Treatment of periprosthetic hip infection involves thorough debridement and administration of adequate local and systemic antibiotics. Initially, a thorough debridement was performed, using a transgluteal approach, to effect the complete removal of all implant components, cement, granulation tissue and necrotic/infected tissues. To ensure a thorough debridement, routine radiographs, computed tomography scans and radioactive isotopes were used to assess necrotic and infected

tissues. Aspiration and periprosthetic tissue specimens were sent for microbiology and pathology studies. The hip joint was exhaustively flushed and then irrigated with hydrogen peroxide solution and povidone iodine. Subsequently, for one-stage revision THAs, all instruments, including the light handle, sucker and electrocautery scalpel, and protective clothing were replaced with fresh, sterile materials. Further, the old drape was covered with a new one, and new sterile instruments were prepared. Appropriate intravenous systemic antibiotic therapy was started and continued for two weeks post-operatively. Subsequently, oral antibiotic therapy, tailored to the clinical signs and CRP levels, was administered for a minimum of three months. In two-stage revision THAs, after thorough debridement, a handmade rod and beads, including adequate high-dose ALAC were temporarily placed. Appropriate intravenous systemic antibiotic therapy was initiated and continued postoperatively for two weeks, followed by oral antibiotic therapy during the period between the initial debridement and the revision THA. At six to eight weeks after the first thorough debridement, the clinical signs and CRP levels were reviewed and a second thorough debridement was performed prior to the THA; the THA, using ALAC, was then performed. The postoperative therapy was identical to that used following one-stage revision THAs. If the debridement failed to control the infection, the two-stage revision THA procedure was repeated. All patients underwent weekly follow-up visits for two months, then at three, six and nine months, and biannually thereafter.

A new scoring system for the preoperative evaluation of one- and two-stage revision THAs was developed, based on the six essential variables previously recognised as major risk factors for infection [6, 7, 9–12]. These included (1) patient's general condition, (2) duration of infection and number of prior operations, (3) present wound complications, (4) the presence of microorganisms, (5) CRP levels and (6) the necessity of bone grafting (Fig. 2). Each parameter received 0–2 points, giving a maximum score of 12 points. After the validity of the new scoring system was confirmed, a retrospective analysis was performed by two orthopaedic surgeons blinded to the scoring outcomes.

Prosthesis survival was analysed using the Kaplan-Meier method, with 95 % confidence intervals (CIs); implant removal due to recurrent infection was considered the end point. Univariate Cox proportional hazards models of the association between risk factors and implant removal were built. All independently associated variables were included in the multivariate Cox analysis. In addition, the first episode of recurrent infection was analysed, but further episodes were censored. The validity of the scoring system was evaluated using receiver-operating characteristic (ROC) curves. The ROC analysis was performed using the parameters identified in the multivariate analysis to define the threshold for implant removal, facilitating the calculation of sensitivity and specificity. Prognostic sensitivity was defined as the total number

Fig. 1 Study flow chart



of cases divided by the number of implant removals. The ROC curve was constructed by plotting the sensitivity, on the vertical axis, and 100 minus the specificity, on the horizontal axis, for a given cut-off point. Using ROC analysis, the thresholds for the best sensitivity and specificity of the scoring system were defined, and thereby the most valuable cut-off point for each score was estimated. A two-way table of the scores and outcomes was constructed to predict the risk of recurrence for each score. All data were analysed using one-way analysis of variance (ANOVA), using SAS version 9.2

(SAS Institute, Cary, NC, USA); a *p* value <0.05 was considered significant.

Results

Patient demographic data are shown in Table 1, and the microorganisms isolated pre- and intraoperatively are shown in Table 2. Among patients undergoing one-stage revision THA, 16 of 17 cases were successful, and among patients undergoing two-stage revision THA, including multiple-stage revision THA, 33 of 38 cases were successful (Fig. 3). The ten year survival rate was 94 % (95 % CI 83–100) for one-stage revision THA and 87 % (95 % CI 76–98) for the two-stage revision THA.

Significant univariate risk factors for implant removal due to recurrent infection were general condition [hazard ratio (HR) 0.13; 95 % CI 0.03–0.51; *p*=0.003], the presence of microorganisms (HR 0.42; 95 % CI 0.18–1.00; *p*=0.049) and CRP level (HR 0.27; 95 % CI 0.08–0.86; *p*=0.027). In the multivariate Cox regression analysis, the total preoperative score was an independent risk factor for implant removal due to recurrent infection (HR 0.17; 95 % CI 0.06–0.49; *p*=0.001). To confirm the validity of the scoring system, the sensitivity and specificity were plotted on an ROC curve (area under the curve 0.97; 95 % CI 0.91–1.00) (Fig. 4a). The sensitivity and specificity, at a scoring system cut-off of 4 points, were 83 and 100 %, respectively; the risk of recurrent infection in patients

Criterion	Points (Total = 12)
1. General condition	
Poor (American Society of Anesthesiologists' class ≥ 3, etc.)	0
Moderate (diabetes mellitus, steroid, autoimmune disease, etc.)	1
Good	2
2. Duration of infection, number of past operations	
Past operations ≥ 2 (including osteotomy, debridement, etc.)	0
Late infection	1
Early or delayed infection	2
3. Present wound complication	
Sinus tract, abscess	0
Slightly damaged (reddish, local heat, etc.)	1
Intact	2
4. Presence of microorganisms	
Methicillin-resistant organisms, Gram-negative organisms	0
Unknown	1
Antibiotic sensitive organisms	2
5. C-reactive protein (mg/L)	
> 50	0
5–50	1
< 5	2
6. Necessity for bone grafting	
Necessary	0
Unnecessary	2

Fig. 2 Pre-operative scoring system

Table 1 Patient demographics

	One-stage revision THA (<i>n</i> =17)	Two-stage revision THA (<i>n</i> =38)
Mean age at time of surgery (years)	69 (52–90)	64 (34–86)
Male to female ratio	5:12	7:31
THA to hemiarthroplasty ratio	11:6	21:17
Mean time from primary procedure to first-stage revision (years)	4 (0.3–12)	4 (0.1–14)
Mean time from first-stage to second-stage revision (weeks)	–	8 (5–13)
Mean time from revised THA to final follow-up (years)	6 (0.7–11)	5 (0.7–10)

The values show the mean (range)

THA total hip arthroplasty

scoring 4 points was 83 %. The risk of infection recurrence is graphically illustrated in Fig. 4b.

The preoperative scores (Fig. 5) for successful cases were 8–12 points for patients undergoing one-stage revision THA and 5–9 points for those undergoing two-stage revision THA. In addition, for patients undergoing one-stage revision THA, the average total pre-operative scores for successful and failed cases were 9.9 and 6.0, respectively. The average total pre-operative scores for patients undergoing successful two-stage revision THAs, multiple-stage revision THAs and failed two-stage revision THAs were 7.2, 5.8 and 3.6, respectively. There were significant differences between the mean preoperative scores of patients undergoing successful one- and two-stage revision THAs ($p < 0.05$). Among patients undergoing two-stage revision THAs, there were significant differences in the mean preoperative scores between the successful and failed cases ($p < 0.05$).

Discussion

The current consensus, based on algorithms and staging systems for periprosthetic hip infections [6–10], is that one-stage revision THA can be performed when required by patient circumstances. However, a scoring system is not available to help determine when a one- or two-stage revision THA surgical strategy is appropriate. We selected individual risk factors, based on the published criteria [6, 7, 9–12], and attempted to set up a new scoring system for pre-operative evaluations.


Despite the promise of the novel scoring system described here, there are some limitations to this study. First, the study sample size was small, involving only 55 individuals. Obtaining a large series from a single institution is difficult, and there have been only five literature reports involving relatively large patient series (>50 patients) from a single institution [15–19]. We considered an analysis from a single

Table 2 Microorganisms isolated pre- and intra-operatively

Isolates	One-stage revision THA	Two-stage revision THA
CNS	4	10
MRSA	2	8
MSSA	1	6
MSSE	3	2
MRSE	1	1
<i>Pseudomonas aeruginosa</i>	0	2
<i>Staphylococcus epidermidis</i>	1	1
MRCNS	0	1
<i>Streptococcus anginosus</i>	0	1
<i>Serratia</i> sp.	0	1
<i>Micrococcus</i> sp.	1	0
<i>Enterococcus</i> sp.	0	1
<i>Peptostreptococcus</i> sp.	0	1
Unknown	6	5

THA total hip arthroplasty, CNS coagulase-negative *Staphylococcus*, MRSA methicillin-resistant *Staphylococcus aureus*, MSSA methicillin-sensitive *Staphylococcus aureus*, MSSE methicillin-sensitive *Staphylococcus epidermidis*, MRSE methicillin-resistant *Staphylococcus epidermidis*, MRCNS methicillin-resistant coagulase-negative *Staphylococcus*

Fig. 3 Radiographs of a 75-year-old woman who underwent two-stage revision THA (scoring system, 7 points). **a** Combined deficiencies, acetabular defect. **b** ALAC beads seven weeks after the first-stage surgery. **c** Five years after reimplantation with allograft reconstruction and a metal ring



institution more valuable as studies included in meta-analyses might include slightly differing techniques performed by surgeons. Second, although the validity of the new scoring system was confirmed (Fig. 4a), confirmation of the veracity of each established parameter was not possible. For example, Wroblewski [12], Elson [15] and Hsieh et al. [20] recommended two-stage revision THAs in cases where bone grafting was necessary, whereas Rudelli et al. [21] reported that among 32 patients, including those with sinus tracts, the recurrence rate was 94 % for one-stage revision THA. Among patients with sinus tracts, Raut et al. [22] and Ure et al. [23] reported that infection was controlled in 90 and 100 % of patients, respectively. Furthermore, in our study, we did not explore other potential variables such as implant loosening, polymicrobial infection and haematogenous infection for the scoring system. Third, some patients, not undergoing implant removal, may have actually had recurrent infections.

However, if these cases were not diagnosed as being infected, according to the working definition, they were not considered recurrent infections. Determination of the necessity of surgical treatment is important, and we defined a failure as an implant removal due to recurrent infection. In addition, the duration of antibiotic therapy after reimplantation during a two-stage revision THA may not be universally consistent. Zimmerli et al. [24] suggested that, in two-stage revision THAs, if intraoperative specimen cultures remain negative, antimicrobial treatment may be discontinued after six weeks; otherwise, therapy should continue for three months. However, our duration was not congruent with international benchmarks.

Jackson and Schmalzried [11] conducted an infection control analysis of 1,299 cases of THA from 12 studies to determine the factors associated with successful patient outcomes. They suggested that cementless implants may be contraindicated in patients requiring one-stage revision THAs. In our

Fig. 4 **a** ROC curves. **b** Percentage risk of recurrence for each score





Fig. 5 Total preoperative scores for patients undergoing one- and two-stage THA



study, the ten year survival rates were 94 and 87 % for one- and two-stage revision THAs, respectively, although selection bias may undermine the validity of this direct comparison. Consequently, one-stage revision THAs involving ALAC gave promising results because of their advantages for the treatment and prevention of infection. According to previous reports (Table 3), some surgeons routinely perform one-stage revision THAs, with infection control rates in six studies reported to be 77–100 % [1, 2, 12, 22, 23, 25]. Others, including our study, selected one-stage revision THA depending on patient requirements and showed infection control rates of 76–100 % in the eight studies [13, 15–19, 26]. These rates

were similar to those reported in studies only performing one-stage revision THAs. The indications for one-stage revision THAs are shown in Table 3, but there are few reports describing the use of definite algorithms [14, 19]. Oussedik et al. [18] suggested that a direct comparison between one- and two-stage revision THA is difficult, given the non-randomised nature of such studies, but that including those patients treated by two-stage revision THA can provide an estimate of the proportion of cases that might be suitable for one-stage revision THA. According to the pre-operative scoring system, there were significant differences between the scores corresponding to successful one- and two-stage revision THAs;

Table 3 Recently published studies reporting relatively large series of one-stage revision THAs from a single institution

First author	Year published	One-stage revision THA		Two-stage revision THA		Indication
		<i>n</i>	Infection control (%)	<i>n</i>	Infection control (%)	
Buchholz [13]	1981	667	77	–	–	No selection
Miley [25]	1982	47	87	–	–	No selection
Wroblewski [12]	1986	102	91	–	–	No selection
Raut [22]	1994	57	86	–	–	No selection
Ure [23]	1998	20	100	–	–	No selection
Callaghan [2]	1999	24	92	–	–	No selection
Sanzén [19]	1988	72	76	30	75	GC, BG
Hope [16]	1989	72	88	19	100	PO, MO, BG
Elson [15]	1993	235	88	61	97	Not described
Garvin [26]	1994	10	90	30	97	DI, WC, MO
Klouche [17]	2000	38	100	46	98	DI, MO, BG
Giulieri [13]	2004	16	94	31	90	Zimmerli's algorithm [10]
Oussedik [18]	2010	11	100	39	95	Haddad's protocol [6]
Our study	2014	17	94	38	87	GC, DI, PO, WC, MO, CRP, BG

THA total hip arthroplasty, GC general condition, BG bone grafting, PO past operations, MO microorganisms, DI duration of infection, WC wound complication, CRP C-reactive protein

one-stage revision THA was recommended in cases scoring more than 9 points (Fig. 5). In contrast, the risk of recurrent infection in patients scoring 4 points was 83 % (Fig. 4).

In conclusion, the novel preoperative scoring system described here was useful for determining the management of periprosthetic hip infections. One-stage revision THA is recommended for patients scoring more than 9 points, and other options should be considered for patients scoring 4 or fewer points in order to minimise the risk of recurrent infection. Additionally, one-stage revision THAs may be possible for cases scoring 7 or 8 points. To fully validate this novel scoring system, a prospective study of the system in a multicentre trial is required.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Buchholz HW, Elson RA, Engelbrecht E, Lodenkämper H, Röttger J, Siegel A (1981) Management of deep infection of total hip replacement. *J Bone Joint Surg Br* 63:342–353
- Callaghan JJ, Katz RP, Johnston RC (1999) One-stage revision surgery of the infected hip. A minimum 10-year followup study. *Clin Orthop Relat Res* 369:139–143
- Garvin KL, Hanssen AD (1995) Infection after total hip arthroplasty. Past, present, and future. *J Bone Joint Surg Am* 77:1576–1588
- Lange J, Troelsen A, Thomsen RW, Søballe K (2012) Chronic infections in hip arthroplasties: comparing risk of reinfection following one-stage and two-stage revision: a systematic review and meta-analysis. *Clin Epidemiol* 4:57–73
- Langlais F (2003) Can we improve the results of revision arthroplasty for infected total hip replacement? *J Bone Joint Surg Br* 85:637–640
- Haddad FS, Masri BA, Garbuz DS, Duncan CP (1999) The treatment of the infected hip replacement. The complex case. *Clin Orthop Relat Res* 369:144–156
- Hanssen AD, Osmon DR (2000) Assessment of patient selection criteria for treatment of the infected hip arthroplasty. *Clin Orthop Relat Res* 381:91–100
- McPherson EJ, Woodson C, Holtom P, Roidis N, Shufelt C, Patzakis M (2002) Periprosthetic total hip infection: outcomes using a staging system. *Clin Orthop Relat Res* 403:8–15
- Parvizi J, Adeli B, Zmistowski B, Restrepo C, Greenwald AS (2012) Management of periprosthetic joint infection: the current knowledge: AAOS exhibit selection. *J Bone Joint Surg Am* 94:e104
- Zimmerli W, Ochsner PE (2003) Management of infection associated with prosthetic joints. *Infection* 31:99–108
- Jackson WO, Schmalzried TP (2000) Limited role of direct exchange arthroplasty in the treatment of infected total hip replacements. *Clin Orthop Relat Res* 381:101–105
- Wroblewski BM (1986) One-stage revision of infected cemented total hip arthroplasty. *Clin Orthop Relat Res* 211:103–107
- Giulieri SG, Graber P, Ochsner PE, Zimmerli W (2004) Management of infection associated with total hip arthroplasty according to a treatment algorithm. *Infection* 32:222–228
- Della Valle C, Parvizi J, Bauer TW, Dicesare PE, Evans RP, Segreti J, Spangehl M, Watters WC, Keith M, Turkelson CM, Wies JL, Sluka P, Hitchcock K, American Academy of Orthopaedic Surgeons (2010) Diagnosis of periprosthetic joint infections of the hip and knee. *J Am Acad Orthop Surg* 18:760–770
- Elson RA (1993) Exchange arthroplasty for infection. Perspectives from the United Kingdom. *Orthop Clin North Am* 24:761–767
- Hope PG, Kristinsson KG, Norman P, Elson RA (1989) Deep infection of cemented total hip arthroplasties caused by coagulase-negative staphylococci. *J Bone Joint Surg Br* 71:851–855
- Klouche S, Leonard P, Zeller V, Lhotellier L, Graff W, Leclerc P, Mamoudy P, Sariali E (2012) Infected total hip arthroplasty revision: one- or two-stage procedure? *Orthop Traumatol Surg Res* 98:144–150
- Oussedik SI, Dodd MB, Haddad FS (2010) Outcomes of revision total hip replacement for infection after grading according to a standard protocol. *J Bone Joint Surg Br* 92:1222–1226
- Sanzén L, Carlsson AS, Josefsson G, Lindberg LT (1988) Revision operations on infected total hip arthroplasties. Two- to nine-year follow-up study. *Clin Orthop Relat Res* 229:165–172
- Hsieh PH, Shih CH, Chang YH, Lee MS, Yang WE, Shih HN (2005) Treatment of deep infection of the hip associated with massive bone loss: two-stage revision with an antibiotic-loaded interim cement prosthesis followed by reconstruction with allograft. *J Bone Joint Surg Br* 87:770–775
- Rudelli S, Uip D, Honda E, Lima AL (2008) One-stage revision of infected total hip arthroplasty with bone graft. *J Arthroplasty* 23:1165–1177
- Raut VV, Siney PD, Wroblewski BM (1994) One-stage revision of infected total hip replacements with discharging sinuses. *J Bone Joint Surg Br* 76:721–724
- Ure KJ, Amstutz HC, Nasser S, Schmalzried TP (1998) Direct-exchange arthroplasty for the treatment of infection after total hip replacement. An average ten-year follow-up. *J Bone Joint Surg Am* 80:961–968
- Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. *N Engl J Med* 351:1645–1654
- Miley GB, Scheller AD Jr, Turner RH (1982) Medical and surgical treatment of the septic hip with one-stage revision arthroplasty. *Clin Orthop Relat Res* 170:76–82
- Garvin KL, Evans BG, Salvati EA, Brause BD (1994) Palacos gentamicin for the treatment of deep periprosthetic hip infections. *Clin Orthop Relat Res* 298:97–105